Mobile

A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW® 2009/2010 injected intramuscularly in young adults (18 to 60 years) ...

Update Il y a 4 ans
Reference: EUCTR2009-010811-34

A Phase III, open, non-randomized, multi-centric, single dose study to assess mmunogenicity and safety of Fluarix / Influsplit SSW® 2009/2010 injected intramuscularly in young adults (18 to 60 years) and in elderly (over 60 years)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the humoral response (anti-hemagglutinin antibody tested by hemagglutination inhibition) against each vaccine strain in adults aged 18 years or above, 21 days after vaccination with Fluarix™/Influsplit SSW® 2009-2010.

Inclusion criteria

  • Immunization against influenza of healthy adults

Links